Kimberly J. Popovits has been a part of 10x Genomics, Inc. since March 2020, stepping in as a director and bringing her extensive experience to the board. She previously served as the President and CEO of Genomic Health, Inc., a...

Kimberly J. Popovits has been a part of 10x Genomics, Inc. since March 2020, stepping in as a director and bringing her extensive experience to the board. She previously served as the President and CEO of Genomic Health, Inc., a company she led until its acquisition in 2019. Popovits held pivotal roles in Genentech during her early career, where she honed her skills in marketing and sales. She also has a strong educational background with a B.A. in Business from Michigan State University. Beyond her role at 10x, she has been active on several boards, including Talis Biomedical Corporation and Kiniksa Pharmaceuticals. Interestingly, in 2023, she reported zero compensation at 10x Genomics, which is quite unique for an executive at her level. This focus on performance over pay highlights her commitment to aligning her interests with the company's success. With her deep roots in healthcare and biotechnology, Popovits' insights guide 10x Genomics as it navigates the complex landscape of genetics and molecular biology.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Talis Biomedical Corporation CEOs

T

Kimberly J. Popovits

Ex-CEO of Talis Biomedical Corporation

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

CEO of Talis Biomedical Corporation for

0 years 3 months (Aug 2021 - Dec 2021)

Previous Experience

Former Chair of the Board of Directors, President and Chief Executive Officer of Genomic Health.

Rivals

Competitors/colleagues of Kimberly J. Popovits

Holdings

See how much did Kimberly J. Popovits make over time.

Kimberly J. Popovits holds a significant position as a director at 10x Genomics, owning shares in the company since her appointment. In her early years, she reported substantial financial rewards as she transitioned from Genomic Health, where she gained her...

Kimberly J. Popovits holds a significant position as a director at 10x Genomics, owning shares in the company since her appointment. In her early years, she reported substantial financial rewards as she transitioned from Genomic Health, where she gained her wealth through stock options and performance-based pay. However, her current holdings in 10x Genomics have likely fluctuated as she has not been awarded stock or bonuses recently, illustrating her unique focus on long-term company performance rather than immediate financial gain. As of now, her compensation reflects a strategic approach, possibly awaiting the right moment to align her holdings with the company's growth, especially with the fast-evolving market in genomics. Investors are keenly interested in how she will leverage her experience and holdings in charting 10x's future.

Mar 18, 2025

K

shares

KNSA @ $22.61

T

shares

TXG @ $10.51

Insider Trading

See recent insider trades of Kimberly J. Popovits.

TXG

8,649 shares

TXG

Jun 11, 2024

Received

TXG

1,865 shares

TXG

Jun 14, 2023

Received

TXG

2,120 shares

TXG

Jun 15, 2022

Received

TXG

625 shares

TXG

Jun 11, 2021

Received

Compensation History

See how much did Kimberly J. Popovits make over time.

In 2023, Kimberly J. Popovits reported a total compensation of $0 at 10x Genomics, which included no salary, bonuses, or stock awards. This zero compensation stands out in comparison to her previous roles, where she garnered significant payouts. For instance, in 2020, she had a total compensation package of $450,000 primarily from her salary and some other benefits, showing her usual trend of variable pay based on performance and company success. Her compensation strategy aligns with a philosophy that values stockholder interests over executive excess. This is a stark shift that some might see as risky, but it reflects a deep commitment to the company's mission rather than personal financial gain. With performance metrics tied to company value creation, Popovits remains a pivotal player in 10x Genomics, emphasizing her focus on growth and results rather than just paycheck figures.

Year

2023

Total Compensation

$0.00

Salary

$0.00

Board Justification

The compensation philosophy emphasizes pay-for-performance and aligns executive compensation with company performance and market benchmarks.

Bonus

$0.00

Board Justification

No bonus was awarded to Kimberly J. Popovits in 2023.

Other

$0.00

Board Justification

No other compensation was reported for Kimberly J. Popovits in 2023.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock awards vested in 2023 for Kimberly J. Popovits.

Performance Metrics

Performance metrics for Kimberly J. Popovits' compensation were based on company performance, but specific metrics were not disclosed.

Other Talis Biomedical Corporation CEOs

Here are other CEOs of Talis Biomedical Corporation

Brian J. Blaser

Ex-CEO of Talis Biomedical Corporation

December 2021 - December 2021